EJNMMI Research最新文献

{"title":"Pre- or post-chemotherapy: effect on PSMA uptake.","authors":"Surekha Yadav, Abuzar Moradi Tuchayi, Moein Moradpour, Fei Jiang, Roxanna Juarez, Ivan de Kouchkovsky, Robert R Flavell, Rahul R Aggarwal, Thomas A Hope","doi":"10.1186/s13550-025-01229-3","DOIUrl":"10.1186/s13550-025-01229-3","url":null,"abstract":"","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"15 1","pages":"36"},"PeriodicalIF":3.1,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143794953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Magnetic resonance spectroscopy for enhanced multiparametric MRI characterization of [¹⁸F]FET PET-negative gliomas.","authors":"Xiaoran Li, Xinru Xiao, Xin Han, Ye Cheng, Bixiao Cui, Meng Zhang, Huawei Liu, Jie Lu","doi":"10.1186/s13550-025-01224-8","DOIUrl":"10.1186/s13550-025-01224-8","url":null,"abstract":"<p><strong>Background: </strong>Approximately 30-36% of gliomas presented with [¹⁸F]fluoroethyl-L-tyrosine ([¹⁸F]FET) PET-negative at primary diagnosis, which interferes with the differentiation of gliomas from other isolated brain lesions. Preoperative noninvasive identification of [¹⁸F]FET PET-negative gliomas to aggressive surgical treatment could reduce ineffective treatment and improve prognosis. This study aimed to assess the potential utility of multiparametric MRI with ¹H-magnetic resonance spectroscopy (¹H-MRS) in the diagnosis of gliomas within [¹⁸F]FET PET-negative isolated cerebral lesions.</p><p><strong>Results: </strong>A total of 51 patients (mean age 44.35 ± 27.15 years, 26 males) with 37 gliomas and 14 non-gliomas were recruited for the study. More than half of PET-negative gliomas presented T2-FLAIR mismatch sign, whereas non-gliomas were more likely to present absence of T2-FLAIR mismatch sign (54.05% vs. 7.14%, p < 0.001). Choline to creatine (Cho/Cr) ratios in gliomas were significantly higher than those in non-gliomas (2.21 vs. 1.30, p < 0.001). Multiparametric MRI (AUC = 0.88) outperformed conventional MRI (AUC = 0.72) in differentiating gliomas from non-gliomas (NRI = 0.29, p = 0.02). And WHO grade was correlated with Cho/Cr and total lesion tracer standardized uptake (TLU) (r = 0.43 and 0.55; p = 0.007 and < 0.001; respectively). Low-grade PET-negative gliomas exhibit low levels of both TLU and Cho/Cr, but the distribution of TLU and Cho/Cr is more variable in high-grade gliomas. Furthermore, there was a moderated correlation between TLU and Cho/Cr in low-grade PET-negative gliomas (r = 0.54, p = 0.017), whereas there was no correlation in the high-grade PET-negative gliomas (r = -0.017, p = 0.95).</p><p><strong>Conclusion: </strong>Multiparametric MRI with ¹H-MRS demonstrates significant promise in enhancing the diagnosis and overall clinical management for [¹⁸F]FET PET-negative gliomas. Moreover, the correlation between TLU and Cho/Cr that was affected by tumor grading of 2021 WHO criteria provides a rationale for further research into the mechanisms of reduced [¹⁸F]FET uptake in gliomas.</p>","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"15 1","pages":"37"},"PeriodicalIF":3.1,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143802710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PET imaging of hepatocellular carcinoma with [¹²⁴I]IV-14.","authors":"Wei Cao, Olga Sergeeva, William Julian, Adam Kresak, Destiny Lusinger, Joseph Schneider, Marc S Berridge, Sandra Sexton, Patrick Wojtylak, Qiubai Li, Wendy Liu, Ernest Ricky Chan, Yogen Saunthararajah, Zhenghong Lee","doi":"10.1186/s13550-025-01227-5","DOIUrl":"10.1186/s13550-025-01227-5","url":null,"abstract":"<p><strong>Background: </strong>Currently, positron emission tomography (PET) plays no clear role in clinical imaging and management of hepatocellular carcinoma (HCC). New radiotracers for new target(s) are needed for PET imaging of HCC. Uridine-cytidine kinase 2 (UCK2) is a rate-limiting enzyme of the pyrimidine salvage synthesis pathway to phosphorylate uridine and cytidine. Studies have demonstrated that UCK2 is overexpressed in many types of solid cancers including HCC and is associated with the poor prognosis and proliferation of HCC. This study reported PET imaging using a UCK2-specific radiotracer with a clinically relevant anima model of spontaneously occurring HCC in the woodchucks.</p><p><strong>Methods: </strong>This study used 3'-(E)-(2-iodovinyl) uridine (IV-14), which is derived from a UCK2-selective antitumor agent 3'-(Ethynyl)uridine (EUrd), a cytotoxic ribonucleoside analogs of uridine. By radiolabeling IV-14 with Iodine-124 (¹²⁴I), a UCK2-specific radiotracer [¹²⁴I]IV-14 was obtained for PET imaging of UCK2. A naturally occurring woodchuck model of HCC following chronic viral hepatitis infection was used for PET imaging. Potassium iodide (KI) was tested in one of the three animals to block possible uptake of free ¹²⁴I from de-iodination of [¹²⁴I]IV-14.</p><p><strong>Results: </strong>We confirmed that UCK2 expression is higher in the woodchuck model of HCC than in the surrounding hepatic tissue, similar to human UCK2 that is highly expressed in human HCC. PET imaging with [¹²⁴I]IV-14 showed a strong uptake in woodchuck HCC with low background uptake at one-hour post-injection. De-iodination did not seem to be an issue for PET imaging.</p><p><strong>Conclusion: </strong>Our results demonstrate that UCK2 is a viable target for imaging HCC and has the potential for targeted endoradiotherapy of HCC.</p>","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"15 1","pages":"35"},"PeriodicalIF":3.1,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143794950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SPECT/CT in addition to subtraction parathyroid scintigraphy in hyperparathyroidism: diagnostic performance in a cohort of predominantly end-stage renal disease patients.","authors":"Worachart Jitrapinate, Yutapong Raruenrom, Nantaporn Wongsurawat, Prakasit Sa-Ngiamwibool, Daris Theerakulpisut","doi":"10.1186/s13550-025-01234-6","DOIUrl":"10.1186/s13550-025-01234-6","url":null,"abstract":"<p><strong>Background: </strong>SPECT/CT has been well established as a valuable technique in nuclear medicine parathyroid imaging, but most previous studies were done in patients with primary hyperparathyroidism. In this retrospective study, we examined the diagnostic performance of [^99mTc]NaTcO4 / [^99mTc]Tc-MIBI planar subtraction parathyroid scintigraphy (PS), SPECT/CT, and a combination of the two in a patient cohort consisting of mostly end-stage renal disease (ESRD) patients with secondary or tertiary hyperparathyroidism, using histopathological results as the reference standard.</p><p><strong>Results: </strong>Among 116 patients included, 98 (84.5%) had ESRD. The overall sensitivity of subtraction PS, SPECT/CT and combined interpretation was 69% (95% confidence interval: 64-73%), 67% (61-72%), and 79% (74-84%), while the specificity was 68% (59-76%), 71% (61-80%), and 60% (50-70%), respectively. For patients without ESRD with predominantly primary hyperparathyroidism, the sensitivity was 93% (70-99%), 89% (57-98%), and 100% (70-100%), and the specificity was 88% (76-94%), 87% (71-95%), and 84% (67-93%), respectively. For those with ESRD with predominantly tertiary and secondary hyperparathyroidism, the sensitivity was 67% (62-72%), 66% (60-71%), 78% (73-83%), and the specificity was 55% (42-67%), 57% (43-70%), and 43% (30-58%), respectively.</p><p><strong>Conclusion: </strong>SPECT/CT was not superior to subtraction PS in ESRD patients with hyperparathyroidism. Combining these two techniques improves sensitivity, but likely with the expense of reduction in specificity. Both planar subtraction PS and SPECT/CT have suboptimal diagnostic performance in ESRD patients compared with non-ESRD patients where these techniques provide impressive sensitivity and specificity.</p>","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"15 1","pages":"34"},"PeriodicalIF":3.1,"publicationDate":"2025-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11972272/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143788053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Construction of a high-sensitivity Cherenkov luminescence endoscopy system for the detection of gastrointestinal cancers.","authors":"Ze Yang, Tian-Tian Pang, Zhuo-Jun Wu, Tian-Yu Yan, Jing-Min Yu, Xin-Yu Wang, Dan Liu, Xiao-Jian Lu, Xiao-Yu Kang, Gui-Yu Li, Cheng Bai, Xiao-Juan Xi, Zu-Hong Tian, Yu Qi, Ming-Ru Zhang, Fei Kang, Jing Wang, Xue-Li Chen, Kai-Chun Wu","doi":"10.1186/s13550-025-01223-9","DOIUrl":"10.1186/s13550-025-01223-9","url":null,"abstract":"<p><strong>Background: </strong>The diagnostic yield of conventional gastrointestinal (GI) endoscopy for early cancers is low because it is mainly based on morphological changes of tumors. Molecular functional changes in tumors precede morphological changes. Cherenkov luminescence endoscopy (CLE) system can perform molecular imaging of GI cancers, achieving early diagnosis of cancers. However, previous CLE systems had only been able to detect Cherenkov luminescence (CL) from about one μCi nuclide at a minimum (in vivo), but the nuclide probe absorbed by the tumor of a patient was often much less than one μCi at a routinely administered dose. This study aims to construct a clinically usable high-sensitivity CLE for molecular imaging of GI cancers.</p><p><strong>Results: </strong>The minimum resolvable radioactivity of the CLE reached 0.020 μCi within 300 s (in vivo), with a sensitivity at the nanocurie for the first time. The detection sensitivity of the CLE increased by up to nearly twenty-two times over the previous system. In tumor-bearing nude mice, CLE could effectively identify all tumors with 100% concordance with both histopathology and PET/CT, and the CL signals of tumors were much stronger than those of the surrounding normal tissues (P < 0.05). The quality of CLE imaging at 60 s was comparable to that at 300 s (signal-to-background ratio, 2.70 ± 0.48 versus 2.98 ± 0.69, P = 0.56).</p><p><strong>Conclusions: </strong>We constructed a high-sensitivity CLE that could detect radionuclides at the nanocurie radioactivity. The CLE could detect cancers accurately through rapid molecular imaging and had the potential for early diagnosis of GI cancers in clinical practice.</p>","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"15 1","pages":"33"},"PeriodicalIF":3.1,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11968626/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143771736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"3'-deoxy-3'-¹⁸F-fluorothymidine PET imaging of lymphoid tissues in patients with advanced non-small cell lung cancer undergoing anti-programmed cell death-1 therapy.","authors":"Masayuki Sato, Yukihiro Umeda, Tetsuya Tsujikawa, Tetsuya Mori, Akikazu Shimada, Tomoaki Sonoda, Makiko Yamaguchi, Chisato Honjo, Yuko Waseda, Yasushi Kiyono, Tamotsu Ishizuka, Hidehiko Okazawa","doi":"10.1186/s13550-025-01225-7","DOIUrl":"10.1186/s13550-025-01225-7","url":null,"abstract":"<p><strong>Background: </strong>Anti-programmed cell death-1 (anti-PD-1) therapy has become the standard immunotherapy for patients with advanced non-small cell lung cancer (NSCLC). However, little is known about the organs influenced by PD-1 inhibitors on a patient's tumor immunity. We examined the changes in lymphoid tissue proliferation before and after PD-1 inhibitor treatment using 3'-deoxy-3'-[¹⁸F]-fluorothymidine (¹⁸F-FLT) positron emission tomography (PET). This study included 25 patients with advanced NSCLC who underwent ¹⁸F-FLT PET before and 2 and 6 weeks after the initiation of PD-1 inhibitor treatment. We determined the average standardized uptake value (SUV_mean) in the spleen, maximum SUV (SUV_max) in the lymph nodes, and the SUV_max, SUV_mean, proliferative vertebral volume (PVV), and total vertebral proliferation (TVP) in the thoracolumbar vertebral bodies using ¹⁸F-FLT PET and blood test data. The relationship between the rate of change in these parameters before and after treatment and the tumor response was evaluated.</p><p><strong>Results: </strong>The baseline ¹⁸F-FLT accumulation in the lymphoid tissues or blood test data between the progressive disease (PD) and non-PD groups were not significantly different. In the spleen and lymph nodes, changes in ¹⁸F-FLT accumulation from baseline to 2 or 6 weeks did not differ between the non-PD and PD groups. However, mediastinal lymph node accumulation tended to increase transiently at week 2 compared to that before treatment initiation (median SUV_max 2.19 vs. 2.64, P = 0.073). Regarding changes in vertebral accumulation in the non-PD group, the SUV_max, and PVV were significantly lower at weeks 2 and 6. In the percent changes in ¹⁸F-FLT accumulation of the vertebrae after the treatment initiation, the PD group was significantly higher than the non-PD group at the 6-week evaluation (median ΔTVP0-6, 17.0% vs. -13.0%, P = 0.0080).</p><p><strong>Conclusions: </strong>In patients with advanced NSCLC who achieved a tumor response, proliferation decreased in the bone marrow, but not in the spleen or lymph nodes, 6 weeks after treatment initiation. ¹⁸F-FLT PET can help monitor changes in tumor immunity in each lymphoid tissue and may serve as a biomarker for the response to immune checkpoint inhibitor therapy.</p>","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"15 1","pages":"32"},"PeriodicalIF":3.1,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11961847/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mid-treatment changes in intra-tumoural metabolic heterogeneity correlate to outcomes in oropharyngeal squamous cell carcinoma patients.","authors":"Yuvnik Trada, Mark T Lee, Michael G Jameson, Phillip Chlap, Paul Keall, Daniel Moses, Peter Lin, Allan Fowler","doi":"10.1186/s13550-025-01226-6","DOIUrl":"10.1186/s13550-025-01226-6","url":null,"abstract":"<p><strong>Background: </strong>This study evaluated mid-treatment changes in intra-tumoural metabolic heterogeneity and quantitative FDG-PET/CT imaging parameters and correlated the changes with treatment outcomes in oropharyngeal squamous cell cancer (OPSCC) patients. 114 patients from two independent cohorts underwent baseline and mid-treatment (week 3) FDG-PET. Standardized uptake value maximum (SUV_max), standardized uptake value mean (SUV_mean), metabolic tumour volume (MTV), and total lesional glycolysis (TLG) were measured. Intra-tumoural metabolic heterogeneity was quantified as the area under a cumulative SUV-volume histogram curve (AUC-CSH). Baseline and relative change (%∆) in imaging features were correlated to locoregional recurrence free survival (LRRFS) using multivariate Cox regression analysis. Patients were stratified into three risk groups utilising ∆AUC-CSH and known prognostic features, then compared using Kaplan-Meier analysis.</p><p><strong>Results: </strong>Median follow up was 39 months. 18% of patients developed locoregional recurrence at 2 years. A decrease in heterogeneity (∆AUC-CSH: 24%) was observed mid-treatment. There was no statistically significant difference in tumour heterogeneity (AUC-CSH) at baseline (p = 0.134) and change at week 3 (p = 0.306) between p16 positive and p16 negative patients. Baseline imaging features did not correlate to LRRFS. However, ∆MTV (aHR 1.04; 95% CI 1.03-1.06; p < 0.001) and ∆AUC-CSH (aHR 0.96; 95% CI 0.94-0.98; p = 0.004) were correlated to LRRFS. Stratification using ∆AUC-CSH and p16 status into three groups showed significant differences in LRR (2 year LRRFS 94%, 79%, 17%; log rank p < 0.001). Stratification using ∆AUC-CSH and ∆MTV into three groups showed significant differences in LRR (2 year LRRFS 93%, 70%, 17%; log rank p < 0.001).</p><p><strong>Conclusion: </strong>Mid-treatment changes in intra-tumoural FDG-PET/CT heterogeneity correlated with treatment outcomes in OPSCC and may help with response prediction. These findings suggest potential utility in designing future risk adaptive clinical trials.</p>","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"15 1","pages":"31"},"PeriodicalIF":3.1,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11961835/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Autoradiographic comparison between [¹¹C]PiB and [¹⁸F]AZD4694 in human brain tissue.","authors":"Antonio Aliaga, Joseph Therriault, Kely Quispialaya, Arturo Aliaga, Peter Kunach, Arthur C Macedo, Robert Hopewell, Nesrine Rahmouni, Jean-Paul Soucy, Gassan Massarweh, Marie-Christine Guiot, Tevy Chan, Jesse Klostranec, Aida Mary Abreu Diaz, Andreia Rocha, Giovanna Carello-Collar, Luiza S Machado, Marco Antônio De Bastiani, Débora Guerini de Souza, Diogo O Souza, Aline R Zimmer, Serge Gauthier, Tharick A Pascoal, Eduardo R Zimmer, Pedro Rosa-Neto","doi":"10.1186/s13550-025-01216-8","DOIUrl":"10.1186/s13550-025-01216-8","url":null,"abstract":"<p><strong>Background: </strong>Amyloid-β imaging through positron emission tomography (PET) has significantly transformed Alzheimer's disease (AD) research. [¹¹C]PiB has been widely used for imaging β-amyloid plaques due to its high affinity and selectivity for amyloid deposits. [¹⁸F]AZD4694 is a more recently developed amyloid-PET imaging agent, which structurally resembles PiB and has less non-specific binding in the white matter than other ¹⁸F-labeled compounds. The purpose of this study is to compare the in vitro binding properties of the amyloid-PET radiotracers [¹¹C]PiB and [¹⁸F]AZD4694 in post-mortem human brain tissue. Total binding was assessed by autoradiography in prefrontal, inferior parietal, posterior cingulate cortices and hippocampal sections of healthy control (HC) and AD autopsy-confirmed brain tissues. Furthermore, the displacement of [¹⁸F]AZD4694 by unlabeled PiB was evaluated in the above-mentioned sections of AD brain tissues.</p><p><strong>Results: </strong>For both radiotracers, we found significant differences (p < 0.0001) between HC and AD tissues binding in the prefrontal cortex ([¹¹C]PiB Cohen's d = 3.424, [¹⁸F]AZD4694 Cohen's d = 5.070), inferior parietal cortex ([¹¹C]PiB Cohen's d = 3.156, [¹⁸F]AZD4694 Cohen's d = 3.959), posterior cingulate cortex ([¹¹C]PiB Cohen's d = 1.781, [¹⁸F]AZD4694 Cohen's d = 3.434), and hippocampus ([¹¹C]PiB Cohen's d = 1.320, [¹⁸F]AZD4694 Cohen's d = 3.696). Higher binding was detected for [¹⁸F]AZD4694 compared to [¹¹C]PiB in AD prefrontal, inferior parietal and posterior cingulate cortices, while binding in the hippocampus was comparable for both radioligands. Strong correlations between [¹⁸]AZD4694 and [¹¹C]PiB were found in the prefrontal (R = 0.959, p < 0.0001), inferior parietal (R = 0.893, p < 0.0001), posterior cingulate (R = 0.838, p = 0.0006) cortices and hippocampus (R = 0.750, p < 0.0001). Bland-Altman analyses revealed strong agreement between [¹¹C]PiB and [¹⁸F]AZD4694 in the prefrontal, inferior parietal, and posterior cingulate cortices, but lower agreement in the hippocampus. Displacement studies confirmed high binding affinity of PiB in all tissues, indicating that both amyloid-PET agents compete for the same binding sites.</p><p><strong>Conclusions: </strong>This head-to-head study provides evidence that while [¹⁸F]AZD4694 and [¹¹C]PiB bindings are highly correlated with both tracers competing for the same binding sites, [¹⁸F]AZD4694 has a slightly higher effect size when comparing between neuropathologically-confirmed AD and HC brain tissues.</p>","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"15 1","pages":"30"},"PeriodicalIF":3.1,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11961831/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Utility of quantitative standardized uptake value from pre-operative bone SPECT/CT for predicting post-surgical MRONJ healing response.","authors":"Jung-Hyun Park, Da-Mi Yoon, Hai-Jeon Yoon, Jin-Woo Kim","doi":"10.1186/s13550-025-01220-y","DOIUrl":"10.1186/s13550-025-01220-y","url":null,"abstract":"<p><strong>Background: </strong>Medication-related osteonecrosis of the jaw (MRONJ) is a challenging condition often associated with long-term use of anti-resorptive medications. Accurate diagnosis is essential, but predicting the prognosis is particularly difficult due to the high likelihood of recurrence after surgery. This study assesses the utility of quantitative values from bone SPECT/CT as predictors of surgical outcomes in MRONJ patients.</p><p><strong>Materials and methods: </strong>We analyzed a cohort of 57 MRONJ patients who underwent surgical treatment. Preoperative bone SPECT/CT scans were used to obtain the maximal SUV (SUVmax) of MRONJ lesions and the ratio of the SUVmax to the mean SUV of a reference region (rSUVmax). Logistic regression analysis was performed to evaluate the relationship between preoperative SUVmax and rSUVmax and surgical outcomes, adjusting for confounders such as age, sex, diabetes, type of bone-modifying agent, MRONJ-affected sites, and stage.</p><p><strong>Results: </strong>Both SUVmax and rSUVmax values increased with the progression from MRONJ stage 1 to stage 3 and were higher in the No Resolution group compared to the Complete Resolution group. Multivariate logistic regression analysis revealed that higher rSUVmax values were significantly associated with poor surgical outcomes (OR, 1.51; 95% CI, 1.07-2.14), whereas SUVmax values were not significantly associated (OR, 1.05; 95% CI, 0.98-1.13). Preoperative MRONJ stages did not significantly predict MRONJ resolution.</p><p><strong>Conclusion: </strong>rSUVmax from bone SPECT/CT may serve as a valuable prognostic tool for assessing MRONJ severity and predicting surgical outcomes. Incorporating rSUVmax measurements into clinical practice could enhance decision-making and improve patient management.</p><p><strong>Clinical trial registration: </strong>None.</p>","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"15 1","pages":"29"},"PeriodicalIF":3.1,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11958904/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reorganization of brain connectivity in post-COVID condition: a ¹⁸F-FDG PET study.","authors":"Antoine Verger, Matthieu Doyen, Sebastien Heyer, François Goehringer, Alexandra Bruyere, Elsa Kaphan, Meriem Chine, Amélie Menard, Tatiana Horowitz, Eric Guedj","doi":"10.1186/s13550-025-01217-7","DOIUrl":"10.1186/s13550-025-01217-7","url":null,"abstract":"<p><strong>Background: </strong>A hypometabolic brain pattern has been reported in patients with post-COVID condition (PCC). The aim of this study was to investigate reorganization in metabolic connectivity in patients with PCC.</p><p><strong>Results: </strong>One hundred eighty-eight patients who underwent brain ¹⁸F-FDG PET for PCC were retrospectively included from two university hospital centres. These patients were age- and sex-matched to 120 healthy controls who underwent brain ¹⁸F-FDG PET before the COVID-19 outbreak. A voxel-based group comparison between patients and controls was performed (p-voxel at 0.005 uncorrected, p-cluster at 0.05 FWE corrected). Interregional correlation analyses of the identified clusters as well as sparse inverse covariance estimations at whole-brain scaling were also conducted. Both analyses were performed at the group level for all patients and then secondarily according to the postinfection delay; 88 and 100 patients, respectively, had a delay of less than or greater than 9 months (± 9 M). Three hypometabolic clusters, namely, the right frontotemporal, right and left cerebellar, were identified from the voxel-based group comparisons of PCC patients. Within this hypometabolic PCC pattern, a modification in metabolic connectivity was observed in patients compared with controls, which was more marked in the + 9 M group than in the - 9 M group. On the other hand, the graph analysis revealed a decrease in connectivity efficiency metrics in the PCC.</p><p><strong>Conclusions: </strong>Metabolic connectivity is modified in patients with PCC within the hypometabolic post-COVID-19 network, with lasting reorganization evolving over time, suggesting functional adaptation.</p>","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"15 1","pages":"28"},"PeriodicalIF":3.1,"publicationDate":"2025-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11954761/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143742656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}